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We compared Roche MONITOR and Organon Teknika NucliSens assays for human immunodeficiency virus
type 1 (HIV-1) RNA in cerebrospinal fluid (CSF). Results of 282 assays were highly correlated (r 5 0.826), with
MONITOR values being 0.29 6 0.4 log10 copies/ml (mean 6 standard deviation) values. Both assays can
reliably quantify HIV-1 RNA in CSF.
Human immunodeficiency virus type 1 (HIV-1) enters the
central nervous system (CNS) during primary HIV infection
and remains in the CNS throughout disease (5, 16). HIV-1
RNA concentrations in cerebrospinal fluid (CSF) correlate
with cognitive abnormalities during AIDS (6, 9). Although
antiretroviral therapy can control HIV-1 replication in periph-
eral tissues, the ability to control HIV-1 in the CNS is less well
established, and there is evidence that some drugs do not
effectively cross the blood-brain barrier (13). Both patient care
and research related to HIV-1 infection of the CNS may ben-
efit from validated methods to quantify virus in CSF.
We compared the performances of two commercially avail-
able HIV-1 RNA assays for quantitation of HIV-1 RNA in
CSF: AMPLICOR HIV-1 MONITOR (Roche Diagnostic Sys-
tems, Branchburg, N.J.), and NucliSens HIV-1 QT (Organon
Teknika, Durham, N.C.). The Roche MONITOR assay em-
ploys reverse transcriptase PCR technology to quantitate
HIV-1 RNA. The Organon-Teknika NucliSens assay uses iso-
thermal amplification of RNA through a process termed nu-
cleic acid sequence-based amplification (14). Previous studies
that compared the NucliSens assay and MONITOR assay us-
ing plasma samples demonstrated comparable sensitivities and
linearities over most of the dynamic range, although the MON-
ITOR assay performed somewhat better at lower HIV-1 RNA
concentrations and NucliSens performed somewhat better at
higher HIV-1 RNA concentrations (1–4, 8, 10, 12). The Nu-
cliSens assay extracts HIV-1 RNA onto silica beads, which may
facilitate quantitation in some body fluids by removing PCR
inhibitors (7). A recent evaluation which failed to detect in-
hibitors in CSF suggested that MONITOR and NucliSens as-
says may be comparable for this fluid (15). The present study
compared to the NucliSens and MONITOR HIV-1 RNA as-
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FIG. 1. Comparison of CSF HIV-1 RNA assay results by NucliSens
assay versus MONITOR assay. (A) Scatter plot of data. The dashed
line indicates the line of unity. (B) Scatter plot of difference between
assay results (MONITOR assay value 2 NucliSens assay value). The
dashed line indicates the mean difference between assay results.
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says in a large number of CSF samples obtained from patients
before and after initiating antiretroviral therapy.
Subjects were HIV positive, antiretroviral naı̈ve, and at least
18 years of age and had pretreatment HIV-1 RNA concentra-
tions in CSF and plasma greater than 2,500 and 25,000 copies/
ml, respectively (by NucliSens assay). Ultraintensive sampling
of CSF via indwelling lumbar catheters was performed as de-
scribed elsewhere (11). Briefly, lumbar CSF was sampled con-
tinuously for 48 h at baseline. Four days after catheter removal,
therapy was initiated with stavudine, lamivudine, and nelfina-
vir. Beginning on treatment day 4, ultraintensive CSF sampling
was again performed for 48 h. A total of 17 baseline and 17
on-treatment CSF samples from each subject, representing
samples collected at 3-h intervals, were analyzed by both Nu-
cliSens and MONITOR assays. Five additional baseline sam-
ples were collected in an identical manner from a fifth subject.
A total of 141 CSF samples were tested by each assay. The
study was approved by the institution’s Committee for the
Protection of Human Subjects, and all participants provided
written informed consent.
NucliSens and MONITOR assays were performed according
to the manufacturers’ instructions using 0.5 to 1.0 ml of CSF
(most assays used 1.0 ml). Statistical analyses were performed
using SPSS version 9.0 (SPSS, Chicago, Ill.). For each subject,
the mean of 17 samples obtained over 48 h at baseline (pre-
treatment) was used to calculate variance. All analyses used
log10-transformed results.
For all CSF samples, HIV-1 RNA concentration ranged
from 65 to 588,844 copies/ml. Viral RNA was detected in every
sample by both assays. Results were less than 1,000 copies/ml
for 21 (14.9%) of the NucliSens assays and 7 (5.0%) of the
MONITOR assays. Results by the two methods were highly
correlated (Fig. 1A) (r 5 0.826; P , 0.001). The mean HIV-1
RNA result by the MONITOR assay was 4.01 log10 copies/ml,
and that by the NucliSens assay was 3.71 log10 copies/ml. For
individual samples, MONITOR assay results were 0.29 6 0.4
log10 copies/ml (mean 6 standard deviation) greater than Nu-
cliSens assay results. This difference was apparent at both high
and low HIV-1 RNA concentrations (Fig. 1B). However, for 29
(20.6%) of the paired assays, the NucliSens result exceeded the
MONITOR result. MONITOR results exceeded NucliSens re-
sults by at least 1.0 log10 in 5 (3.5%) of samples. For samples
with NucliSens assay results between 3.5 and 4.5 log10 copies/
ml, the difference between assays was somewhat less. Within
this range, MONITOR assay results were only 0.13 6 0.34
log10 copies/ml greater than NucliSens assay results.
We next examined assay variance about the mean for each
subject at baseline (Table 1). We previously established that
baseline HIV-1 RNA levels in CSF were constant over 48-h
intervals in these patients (11). Mean variance did not differ
significantly between MONITOR (0.036 log10 copies/ml) and
NucliSens (0.019 log10 copies/ml) assays (P 5 0.20).
Inherent assay variability for plasma HIV-1 RNA level de-
terminations is approximately 0.3 log10 copies/ml. While this is
acceptable for clinical practice, more precise quantitation may
be necessary for research studies of HIV-1 pathogenesis and
treatment effect in CSF, especially if only single-timepoint CSF
samples are available for analysis. We therefore characterized
the extent to which repeated assays on baseline samples im-
proved accuracy. The mean of 17 baseline CSF HIV-1 RNA
determinations was assumed to represent the actual baseline
HIV-1 RNA concentration. In addition to single determina-
tions, for each patient we calculated means for every possible
combination of two, three, four, or five baseline assays (Table
2). For 17 separate baseline assays there are 6,188 unique
five-way combinations from which means can be calculated.
Single assays for both the NucliSens and MONITOR meth-
ods provided results within 0.3 log10 copies/ml of the actual
value in more than 90% of cases. By comparison, to achieve
results within 0.2 log10 copies/ml of the actual value in more
than 90% of cases required single NucliSens assays and tripli-
cate MONITOR assays. To achieve results within 0.1 log10
copies/ml of the actual value in more than 90% of cases re-
quired four NucliSens assays and more than five MONITOR
assays. These results suggest that the NucliSens assay can
achieve somewhat greater accuracy with fewer replicates.
In summary, this study of HIV-1 in CSF established a strong
correlation between results generated by NucliSens and MON-
ITOR assays. MONITOR assay results using CSF are on av-
erage approximately twofold higher than by NucliSens assay.
This is consistent with what has been reported for plasma
samples (8). For clinical practice, NucliSens and MONITOR
assays are of comparable utility for quantifying HIV-1 RNA in
CSF. For research studies, the NucliSens assay may achieve
somewhat greater accuracy with fewer replicates.
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TABLE 1. Determinations of HIV-1 RNA in CSF by MONITOR
assay and NucliSens assay at baseline
Patient no. No. ofsamples





1 17 3.345 0.034 3.959 0.045
2 17 4.681 0.015 5.313 0.071
3 17 4.317 0.011 4.551 0.017
4 17 4.061 0.012 4.102 0.025
5 5 4.072 0.024 3.773 0.023
TABLE 2. Effect on accuracy of performing replicate HIV-1 RNA
assays with CSF
Log10copies/ml
% of means within range of actual value when the
indicated no. of assays was used to calculate each mean
1 2 3 4 5
NucliSens
6 0.1 60.3 73.7 84.9 91.8 95.3
6 0.2 91.2 97.4 99.2 99.8 100.0
6 0.3 97.1 99.8 100.0 100.0 100.0
MONITOR
6 0.1 39.7 56.1 68.8 77.2 83.4
6 0.2 69.1 87.3 94.0 97.2 98.8
6 0.3 91.2 96.9 99.2 99.9 100.0
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